Astri Therapeutics Inc (ATXS)

$6.18 -0.35 (-5.36%)
Market Cap 367.39M
Revenue (ttm) 0.00
Net Income (ttm) -94.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 235,500
Avg Vol 274,958
Day's Range N/A - N/A
Shares Out 56.44M
Stochastic %K 10%
Beta 0.48
Analysts Strong Sell
Price Target $29.33

Company Profile

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatm...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 349 1971
Fax: 617 273 2637
Address:
22 Boston Wharf Road, 10th floor, Boston, United States
Magic8BallResponse
Magic8BallResponse Sep. 20 at 6:24 PM
$ATXS Jill is sitting on a gold mine...... TO THE MOON
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 19 at 7:02 PM
$ATXS THIS MIGHT BE THE TIME
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 19 at 3:16 PM
$ATXS PT raisee to $20!!!!!
0 · Reply
JarvisFlow
JarvisFlow Sep. 17 at 3:46 PM
HC Wainwright & Co. has adjusted their stance on Astria Therapeutics ( $ATXS ), setting the rating to Buy with a target price of 16 → 20.
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 17 at 3:23 PM
$TIL Testing support. Could reverse on news. $ATXS to the moon
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 17 at 2:55 PM
$TIL Flirting with support... needs a buyer..... $ATXS looks like GOLD
0 · Reply
DARKP00L
DARKP00L Sep. 17 at 1:43 PM
$ATXS 09:42 on Sep. 17 2025 ATXS stock has given up its prior loss. Astria Therapeutics shares were trading lower. The company announced initial results from the Phase 1a trial of STAR-0310 in healthy subjects. #tradeideas
0 · Reply
highnihilism
highnihilism Sep. 17 at 9:47 AM
IWM: Russell 2000 → $ATXS Astria Therapeutics $PLX Protalix Biotherapeutics $DAWN Day One Biopharmaceuticals $IMXI International Money Express $DSGN Design Therapeutics
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 16 at 10:21 PM
$TIL $ATXS
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 13 at 3:38 PM
$ATXS It's time for Jill to shine..... PT $9....
0 · Reply
Latest News on ATXS
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology

Sep 17, 2025, 8:00 AM EDT - 3 days ago

Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology

Astria Therapeutics, Inc. (ATXS) Presents at Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 2:07 AM EDT - 15 days ago

Astria Therapeutics, Inc. (ATXS) Presents at Cantor Global Healthcare Conference 2025 Transcript

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 3, 2025, 4:10 PM EDT - 17 days ago

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025

Sep 3, 2025, 8:00 AM EDT - 17 days ago

Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025

Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference

Aug 27, 2025, 8:00 AM EDT - 24 days ago

Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference

Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 12, 2025, 4:10 PM EDT - 5 weeks ago

Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan

Aug 6, 2025, 8:00 AM EDT - 6 weeks ago

Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan

Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit

Jul 7, 2025, 8:00 AM EDT - 2 months ago

Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit

Jun 18, 2025, 8:00 AM EDT - 3 months ago

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

Jun 13, 2025, 7:00 AM EDT - 3 months ago

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress

Jun 6, 2025, 8:00 AM EDT - 3 months ago

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress

Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 4 months ago

Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop

May 23, 2025, 8:00 AM EDT - 4 months ago

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

May 22, 2025, 8:00 AM EDT - 4 months ago

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 13, 2025, 4:10 PM EDT - 4 months ago

Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology

May 1, 2025, 8:00 AM EDT - 5 months ago

Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference

Apr 30, 2025, 8:00 AM EDT - 5 months ago

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Mar 11, 2025, 8:00 AM EDT - 6 months ago

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Feb 27, 2025, 8:00 AM EST - 7 months ago

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 8:00 AM EST - 7 months ago

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

Feb 20, 2025, 8:00 AM EST - 7 months ago

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

Astria Therapeutics: A High-Conviction Bet On HAE

Feb 17, 2025, 10:32 PM EST - 7 months ago

Astria Therapeutics: A High-Conviction Bet On HAE

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 8 months ago

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

Feb 3, 2025, 8:00 AM EST - 8 months ago

Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Jan 23, 2025, 8:00 AM EST - 8 months ago

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

Jan 13, 2025, 8:00 AM EST - 8 months ago

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

Dec 11, 2024, 8:00 AM EST - 10 months ago

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Dec 10, 2024, 8:00 AM EST - 10 months ago

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Nov 27, 2024, 8:00 AM EST - 10 months ago

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Nov 13, 2024, 4:10 PM EST - 11 months ago

Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 11 months ago

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting

Oct 30, 2024, 8:00 AM EDT - 11 months ago

Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Oct 21, 2024, 8:00 AM EDT - 11 months ago

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics' Investigational Therapy for the Treatment of Hereditary Angioedema

Oct 16, 2024, 8:00 AM EDT - 1 year ago

European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics' Investigational Therapy for the Treatment of Hereditary Angioedema

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema

Astria Therapeutics to Present at Upcoming Global Angioedema Forum

Sep 27, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming Global Angioedema Forum

Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress

Astria Therapeutics to Present at Upcoming Bradykinin Symposium

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming Bradykinin Symposium

Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference

Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aug 12, 2024, 4:10 PM EDT - 1 year ago

Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics Chooses Ypsomed's YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema

Aug 12, 2024, 4:00 PM EDT - 1 year ago

Astria Therapeutics Chooses Ypsomed's YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema

Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

May 30, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

May 23, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 9, 2024, 4:10 PM EDT - 1 year ago

Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting

May 8, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting

Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

Mar 25, 2024, 7:30 AM EDT - 1 year ago

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Mar 4, 2024, 4:10 PM EST - 1 year ago

Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting

Feb 20, 2024, 8:00 AM EST - 1 year ago

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting

Magic8BallResponse
Magic8BallResponse Sep. 20 at 6:24 PM
$ATXS Jill is sitting on a gold mine...... TO THE MOON
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 19 at 7:02 PM
$ATXS THIS MIGHT BE THE TIME
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 19 at 3:16 PM
$ATXS PT raisee to $20!!!!!
0 · Reply
JarvisFlow
JarvisFlow Sep. 17 at 3:46 PM
HC Wainwright & Co. has adjusted their stance on Astria Therapeutics ( $ATXS ), setting the rating to Buy with a target price of 16 → 20.
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 17 at 3:23 PM
$TIL Testing support. Could reverse on news. $ATXS to the moon
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 17 at 2:55 PM
$TIL Flirting with support... needs a buyer..... $ATXS looks like GOLD
0 · Reply
DARKP00L
DARKP00L Sep. 17 at 1:43 PM
$ATXS 09:42 on Sep. 17 2025 ATXS stock has given up its prior loss. Astria Therapeutics shares were trading lower. The company announced initial results from the Phase 1a trial of STAR-0310 in healthy subjects. #tradeideas
0 · Reply
highnihilism
highnihilism Sep. 17 at 9:47 AM
IWM: Russell 2000 → $ATXS Astria Therapeutics $PLX Protalix Biotherapeutics $DAWN Day One Biopharmaceuticals $IMXI International Money Express $DSGN Design Therapeutics
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 16 at 10:21 PM
$TIL $ATXS
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 13 at 3:38 PM
$ATXS It's time for Jill to shine..... PT $9....
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 13 at 3:36 PM
$TIL CFO sale + ATM = Shift to $SMMT & $ATXS
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 13 at 1:28 PM
$TIL CFO selling not a great sign. ATM facility possible drag. $ATXS with a great looking chart.
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 11 at 2:45 PM
$ATXS Chart looks goooood
0 · Reply
RunnerSignals
RunnerSignals Sep. 9 at 8:50 PM
$ATXS $DNTH $SION $SEZL $SDGR analysts see stars, but will these rockets launch? Strap in, it's gonna be a wild ride! https://stocksrunner.com/news/2025-09-09-unlocking-stocks-with-analyst-upgrades-and-short-term-upside-potential
0 · Reply
G101SPM
G101SPM Sep. 9 at 2:54 PM
G101SPM 8/6/2025, 8:36:54 AM $ATXS $7.17 bid. DAC $7.60. EXIT $14.00.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 5 at 3:16 PM
$ATXS Brilliant piece that captures ATXS's situation perfectly. So if you want to update your understanding of ATXS or get to know ATXS better, this is essential reading. https://beyondspx.com/quote/ATXS/astria-therapeutics-unlocking-value-through-a-differentiated-dual-asset-pipeline-nasdaq-atxs#analysis
0 · Reply
Magic8BallResponse
Magic8BallResponse Sep. 3 at 11:06 PM
$ATXS Let's get that $8
0 · Reply
Magic8BallResponse
Magic8BallResponse Aug. 24 at 1:51 PM
$ATXS This is a winner.
0 · Reply
DepthLine
DepthLine Aug. 23 at 6:20 AM
$ATXS Astria Therapeutics is a biotech company with focused pipeline in allergic conditions and clinical milestones ahead
0 · Reply
JarvisFlow
JarvisFlow Aug. 13 at 2:20 PM
JMP Securities has adjusted their stance on Astria Therapeutics ( $ATXS ), setting the rating to Market Outperform with a target price of 25 → 26.
0 · Reply
JarvisFlow
JarvisFlow Aug. 13 at 11:30 AM
HC Wainwright & Co. has adjusted their stance on Astria Therapeutics ( $ATXS ), setting the rating to Buy with a target price of 16.
0 · Reply
prismmarketview
prismmarketview Aug. 6 at 3:23 PM
(NASDAQ: $ATXS) @AstriaTx partners with Kaken Pharma to bring navenibart, a potential HAE treatment, to Japan with a $16M deal and milestone payments ahead. https://prismmarketview.com/astria-therapeutics-signs-licensing-deal-with-kaken-pharmaceutical-for-hae-treatment-development-in-japan/
0 · Reply